<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candida infections in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candida infections in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candida infections in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Judith R Campbell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Debra L Palazzi, MD, MEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical manifestations of infection with <em>Candida </em>species range from local mucous membrane infection to widespread dissemination with multisystem organ failure. <em>Candida</em> are considered normal flora in the gastrointestinal and genitourinary tracts of humans but invade and cause disease when there is an imbalance in their ecologic niche.</p><p>This topic will provide an overview of <em>Candida</em> infections in children. Many of these infections are discussed in detail in other topic reviews; they are briefly summarized here. The clinical features, diagnosis, and treatment of candidemia in children and <em>Candida</em> infections in neonates are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6014.html" rel="external">"Candidemia and invasive candidiasis in children: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a>.)</p><p></p><p class="headingAnchor" id="H1198561"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The immune response of the host is an important determinant of the type of infection caused by <em>Candida</em>.</p><p class="bulletIndent1"><span class="glyph">●</span>The most benign infections are characterized by local overgrowth on skin or mucous membranes as a result of changes in the normal microbiota. More extensive and/or persistent mucous membrane infections occur in individuals with deficiencies in cell-mediated immunity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Candidemia results when <em>Candida</em> species gain access to the bloodstream, typically in immune-compromised individuals or patients in the intensive care unit or with vascular devices. Widespread dissemination may occur in neonates, neutropenic hosts, or severely ill patients in the intensive care unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive focal infections, such as endocarditis and meningitis, most often occur after hematogenous spread in patients with anatomic abnormalities or devices (eg, prosthetic heart valves, central nervous system shunts).</p><p></p><p class="headingAnchor" id="H3107054470"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The different <em>Candida</em> species generally are capable of producing all of the clinical syndromes, although infection with <em>Candida albicans </em>is the most common. The major reason to identify the infecting <em>Candida</em> species is that they have different susceptibility profiles (eg, <em>Candida glabrata</em> and <em>Candida krusei</em> are less susceptible to azole antifungal agents than are other species, <em>Candida lusitaniae</em> may be resistant to amphotericin B, and Candida auris are often resistant to both <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> and amphotericin B).</p><p class="headingAnchor" id="H3"><span class="h1">OROPHARYNGEAL CANDIDIASIS</span></p><p class="headingAnchor" id="H364112468"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Oropharyngeal candidiasis (thrush) is common in young infants. It also may be seen in older children treated with antibiotics, inhaled glucocorticoids (for asthma or rhinitis), chemotherapy, or radiation therapy and in children with cellular immune deficiency, such as acquired immunodeficiency syndrome. (See  <a class="medical medical_review" href="/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Topical candidiasis'</a>.)</p><p>Pseudomembranous oropharyngeal candidiasis is the most common form of oropharyngeal candidiasis. It is characterized by white plaques on the buccal mucosa, palate, tongue, or the oropharynx  (<a class="graphic graphic_picture graphicRef69465" href="/d/graphic/69465.html" rel="external">picture 1</a>). Infants with thrush may be asymptomatic or may refuse to eat and swallow because of pain. Older children may be asymptomatic or may complain of a "cottony" feeling in the mouth, loss of taste, and sometimes pain on eating and swallowing.</p><p>Other forms of oropharyngeal candidiasis include angular cheilitis (perlèche) and acute atrophic candidiasis (glossitis).</p><p class="bulletIndent1"><span class="glyph">●</span>Angular cheilitis is characterized by painful fissuring at the corners of the mouth  (<a class="graphic graphic_picture graphicRef71723" href="/d/graphic/71723.html" rel="external">picture 2</a>). It may occur in immunocompromised children and children who habitually lick the corners of the mouth, creating an environment in which <em>Candida</em> can establish an infection. (See  <a class="medical medical_review" href="/d/html/13654.html" rel="external">"Cheilitis", section on 'Angular cheilitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute atrophic candidiasis is characterized by erosion of the papillae on the tongue accompanied by erythema and pain  (<a class="graphic graphic_picture graphicRef54472" href="/d/graphic/54472.html" rel="external">picture 3</a>). It is caused by alteration of the bacterial microbiota of the oral mucosa.</p><p></p><p class="headingAnchor" id="H185638207"><span class="h2">Evaluation and diagnosis</span><span class="headingEndMark"> — </span>Oropharyngeal candidiasis is usually diagnosed clinically, based upon the characteristic white plaques  (<a class="graphic graphic_picture graphicRef69465" href="/d/graphic/69465.html" rel="external">picture 1</a>). If necessary, it can be confirmed by scraping the lesions with a tongue depressor and performing a Gram stain or potassium hydroxide (KOH) preparation on the scrapings. Demonstration of budding yeasts with or without hyphae confirms the diagnosis  (<a class="graphic graphic_picture graphicRef79879" href="/d/graphic/79879.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p>We do not routinely obtain cultures in children with oropharyngeal candidiasis. However, for children with recalcitrant or recurrent oropharyngeal candidiasis, and children who have received antifungal prophylaxis with an azole agent (eg, <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>) and therefore are at greater risk for infection with an azole-resistant species, we obtain cultures to evaluate the possibility of an unusual or azole-resistant species (eg, <em>C. glabrata</em>, <em>C. krusei</em>).</p><p>We suggest evaluation for cellular immune deficiency, including human immunodeficiency virus (HIV) testing, for children with recalcitrant, recurrent, or extensive oropharyngeal candidiasis. Evaluation for cellular immune deficiency also may be warranted for children ≥12 months of age who develop oropharyngeal candidiasis in the absence of a predisposing factor (eg, recent antibiotics, inhaled glucocorticoids, cancer, etc). (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system", section on 'Defects in cellular immunity'</a> and  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a> and  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months", section on 'Diagnostic tests'</a>.)</p><p class="headingAnchor" id="H3789983392"><span class="h2">Management</span><span class="headingEndMark"> — </span>Management of oral candidiasis varies with age, severity of infection, and the immune competence of the host  (<a class="graphic graphic_algorithm graphicRef115621" href="/d/graphic/115621.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>).</p><p>The treatment recommendations provided below are consistent with those in the 2016 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1197660023"><span class="h3">Infants &lt;1 month</span><span class="headingEndMark"> — </span>The management of oropharyngeal candidiasis in neonates is discussed separately. (See  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates", section on 'Mucocutaneous candidiasis'</a>.)</p><p class="headingAnchor" id="H568848526"><span class="h3">Infants 1 through 11 months</span><span class="headingEndMark"> — </span>The successful treatment of oropharyngeal candidiasis in infants involves measures to prevent reinfection and antifungal therapy  (<a class="graphic graphic_algorithm graphicRef115621" href="/d/graphic/115621.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of reinfection</strong> – Measures to prevent reinfection include sterilization or decolonization of items and body sites that are placed in the infant's mouth [<a href="#rid2">2</a>]. Bottle nipples and pacifiers that are to be reused should be boiled after each use.</p><p></p><p class="bulletIndent1">The treatment of <em>Candida</em> breast colonization and/or infection in lactating women is discussed separately. (See  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Candidal infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunocompetent infants</strong> – For immunocompetent infants 1 through 11 months of age, we suggest treatment with topical rather than systemic antifungal therapy  (<a class="graphic graphic_algorithm graphicRef115621" href="/d/graphic/115621.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Candidal infection'</a>.)</p><p></p><p class="bulletIndent2">We initiate treatment for oral candidiasis in immunocompetent infants age one through 11 months with <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> suspension 200,000 units (100,000 units to each cheek) four times daily for 7 to 14 days [<a href="#rid2">2,3</a>]. We prefer nystatin to oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> because nystatin is less expensive and to <a class="drug drug_pediatric" data-topicid="13333" href="/d/drug information/13333.html" rel="external">gentian violet</a> because gentian violet may increase the risk of cancer and can stain the infant's lips and clothing [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">Nystatin</a> suspension may be squirted into the mouth or applied with gauze or cotton swab. Treatment is continued until two to three days after resolution of lesions, which typically occurs within two weeks. Failure to improve or resolve within two weeks may be related to persistent reexposure (eg, from pacifiers or bottle nipples) or infection with an unusual species.</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="13333" href="/d/drug information/13333.html" rel="external">Gentian violet</a> (0.5 or 1 percent) applied to the buccal mucosa once or twice daily is also effective [<a href="#rid3">3</a>]. However, gentian violet is associated with increased risk of cancer, can stain the infant's lips and clothing, and may cause irritation and ulceration [<a href="#rid4">4-7</a>]. Given the availability of other effective agents, we generally do not suggest gentian violet.</p><p></p><p class="bulletIndent2">In randomized trials, 10 to 21 days of treatment with <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> suspension was associated with clinical cure rates of 29 to 80 percent [<a href="#rid8">8-10</a>]. Oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> may be used as an alternative to nystatin. In a randomized trial, compared with nystatin, oral fluconazole was associated with faster clearance of lesions, increased clinical cure rates (100 percent versus 29 percent), and increased mycologic cure rates (73 versus 6 percent); the rates of side effects were similar [<a href="#rid9">9</a>]. However, given the typically benign clinical course of oropharyngeal candidiasis in immunocompetent infants, we suggest nystatin as the initial treatment.</p><p></p><p class="bulletIndent2">Our suggestion to treat immune-competent infants with thrush whether or not they have symptoms is consistent with the recommendations of the IDSA, which are endorsed by the American Academy of Pediatrics [<a href="#rid1">1</a>]. For infants &lt;8 weeks of age, the National Institute for Health and Care Excellence guidelines suggest antifungal therapy if the infant has symptoms (eg, pain, poor feeding) or the infant is breastfed and the mother has symptoms or signs of <em>Candida</em> infection (eg, breast pain, shiny or flaky skin of the nipple) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory thrush in immunocompetent infants and initial treatment of thrush in immunocompromised infants </strong>– For thrush that is refractory to <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a>, appropriate decolonization/sterilization measures in immunocompetent infants, and initial treatment of thrush in immunocompromised infants, we recommend systemic rather than topical antifungal therapy  (<a class="graphic graphic_algorithm graphicRef115621" href="/d/graphic/115621.html" rel="external">algorithm 1</a>). Systemic therapy is well tolerated and more effective [<a href="#rid12">12,13</a>]. We use <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> 3 to 6 mg/kg orally once per day (maximum dose 200 mg) for a total of 7 to 14 days.</p><p></p><p class="bulletIndent2">For infants with oral thrush that does not respond to oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>, we obtain fungal culture and susceptibility testing. We also perform evaluation for immune deficiency (if not previously performed). (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system", section on 'Evaluation for specific types of disorders'</a>.)</p><p></p><p class="headingAnchor" id="H3576298337"><span class="h3">Children ≥12 months</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of severity</strong> – Standardized severity assessments for oropharyngeal candidiasis in children are lacking. We define severity clinically as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild thrush – Involves &lt;50 percent of the oral mucosa and absence of deep, erosive lesions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate/severe thrush – Involves ≥50 percent of the oral mucosa or deep, erosive lesions  (<a class="graphic graphic_picture graphicRef116009" href="/d/graphic/116009.html" rel="external">picture 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to initial antifungal therapy</strong> — Our approach to antifungal therapy varies with severity and immune competence of the child  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild thrush in immunocompetent children</strong> – For mild oropharyngeal candidiasis in immunocompetent children ≥12 months, we suggest topical rather than systemic antifungal therapy  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>). We use topical <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> or <a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">clotrimazole</a>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">Nystatin</a> suspension 400,000 to 600,000 units four times per day for 7 to 14 days. Nystatin suspension should be swished and held in the mouth as long as possible before swallowing; the suspension can be squirted into the mouth for children who are unable to swish and swallow.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">Nystatin</a> lozenge 200,000 units to 400,000 units (one to two lozenges) four times per day for 7 to 14 days.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">Clotrimazole</a> 10 mg (one lozenge) five or six times per day for 7 to 14 days.</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">Nystatin</a> and <a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">clotrimazole</a> lozenges are a choking hazard and should not be used in children younger than four years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild thrush in immunocompromised children and moderate/severe thrush in all children</strong> – For mild thrush in immunocompromised children ≥12 months and moderate/severe thrush  (<a class="graphic graphic_picture graphicRef116009" href="/d/graphic/116009.html" rel="external">picture 5</a>) in all children ≥12 months, we recommend systemic rather than topical antifungal therapy  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>). Systemic therapy is well tolerated and more effective [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent2">We generally use oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">Fluconazole</a> 6 mg/kg orally once on the first day (maximum dose 200 mg for non-HIV-exposed/positive children, 400 mg for HIV-exposed/positive), followed by 3 mg/kg once per day (maximum dose 100 mg for non-HIV-exposed/positive children, 400 mg for HIV-exposed/positive children) for a total of 7 to 14 days</p><p></p><p class="bulletIndent2">Immunocompromised patients with thrush and significant oropharyngeal pain (ie, pain that interferes with eating) may require intravenous antifungal therapy (eg, <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> 6 mg/kg intravenously once on the first day, followed by 3 mg/kg once per day for at least 14 days).</p><p></p><p class="bulletIndent2">In a randomized trial in immunocompromised children (including those with malignancy, immune disorder, HIV, and those receiving immunosuppressive therapy) with oropharyngeal candidiasis, more patients treated with <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> achieved clinical cure (91 versus 51 percent) and mycologic cure (76 versus 11 percent) [<a href="#rid13">13</a>]. In a meta-analysis of 22 studies assessing treatment for oropharyngeal candidiasis in patients with HIV infection, treatment with fluconazole was superior to <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> for clinical cure in adults [<a href="#rid12">12</a>]. Clinical cure rates were similar among patients treated with fluconazole, <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a>, <a class="drug drug_pediatric" data-topicid="13396" href="/d/drug information/13396.html" rel="external">itraconazole</a> solution, <a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">clotrimazole</a> troches, and <a class="drug drug_pediatric" data-topicid="12997" href="/d/drug information/12997.html" rel="external">posaconazole</a> solution, but fluconazole and itraconazole solution were superior to clotrimazole troches for mycologic cure.</p><p></p><p class="bulletIndent2">Given the potential for serious adverse effects, oral <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> tablets should not be used in the treatment of mucocutaneous candidiasis [<a href="#rid14">14</a>]. For additional information, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory thrush in children ≥12 months</strong> – For immunocompetent children with mild thrush that persists despite topical antifungal therapy, we suggest oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1">For immunocompetent or immunocompromised children, moderate to severe oropharyngeal candidiasis that is refractory to oral or intravenous <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> generally is treated intravenously with amphotericin (deoxycholate or lipid formulation) or an echinocandin (eg, <a class="drug drug_pediatric" data-topicid="12914" href="/d/drug information/12914.html" rel="external">caspofungin</a>, <a class="drug drug_pediatric" data-topicid="130086" href="/d/drug information/130086.html" rel="external">anidulafungin</a>, <a class="drug drug_pediatric" data-topicid="12713" href="/d/drug information/12713.html" rel="external">micafungin</a>), given the possibility of fluconazole resistance  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1">In addition to a change in empiric antifungal therapy, culture of the lesions and evaluation for cellular immune deficiency may be warranted. (See <a class="local">'Evaluation and diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system", section on 'Defects in cellular immunity'</a> and  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a> and  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months", section on 'Diagnostic tests'</a>.)</p><p></p><p class="headingAnchor" id="H364112951"><span class="h1">DIAPER DERMATITIS</span><span class="headingEndMark"> — </span><em>Candida</em> diaper dermatitis is common in young infants. It is typically caused by <em>C. albicans</em>. The rash of <em>Candida</em> diaper dermatitis classically occurs in the inguinal region and has areas of confluent erythema with discrete erythematous papules and plaques, superficial scale, and satellite lesions  (<a class="graphic graphic_picture graphicRef59361 graphicRef72165 graphicRef134230" href="/d/graphic/59361.html" rel="external">picture 6A-C</a>).</p><p><em>Candida</em> diaper dermatitis is usually diagnosed clinically, based upon the location and appearance of the rash. If necessary, the diagnosis can be confirmed by scraping the lesions and performing a Gram stain or potassium hydroxide (KOH) preparation on the scrapings. Budding yeasts with or without hyphae establish the diagnosis. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p>The treatment of <em>Candida</em> diaper dermatitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/5795.html" rel="external">"Diaper dermatitis"</a>.)</p><p>Persistent <em>Candida</em> diaper dermatitis in young children may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immunodeficiency. (See  <a class="medical medical_review" href="/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Young children'</a> and  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a>.)</p><p class="headingAnchor" id="H522962008"><span class="h1">INTERTRIGO</span><span class="headingEndMark"> — </span><em>Candida</em> intertrigo refers to <em>Candida</em> infection of closely opposed skin surfaces (eg, neck folds in infants, the axillae, intergluteal folds, etc). Clinical features include erythematous, macerated plaques and erosions with peripheral scale, and satellite papulopustules  (<a class="graphic graphic_picture graphicRef62523" href="/d/graphic/62523.html" rel="external">picture 7</a>). The lesions may be painful if skin breakdown accompanies the infection. The diagnosis and treatment of <em>Candida</em> intertrigo are discussed separately. (See  <a class="medical medical_review" href="/d/html/115366.html" rel="external">"Intertrigo"</a>.)</p><p class="headingAnchor" id="H364112958"><span class="h1">VULVOVAGINITIS</span><span class="headingEndMark"> — </span>Predisposing factors for vulvovaginal candidiasis in infants include diaper use, broad-spectrum antibiotics, and immunosuppression (including glucocorticoids and HIV infection). Additional risk factors in adolescents include certain contraceptive devices (vaginal sponges, diaphragms, intrauterine devices), estrogen therapy (including oral contraceptives), and pregnancy. (See  <a class="medical medical_review" href="/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p>The primary clinical manifestations of <em>Candida</em> vulvovaginitis are itching and discharge. Dysuria and vaginal irritation also may be present. Dyspareunia may be a complaint in sexually active adolescents. Examination shows vulvar erythema and swelling and vaginal erythema and discharge, which is classically curd-like but may be watery. Some patients, primarily those with <em>C. glabrata</em> infection, have little discharge and often only erythema on vaginal examination [<a href="#rid15">15</a>].</p><p>The diagnosis of <em>Candida</em> vulvovaginitis is typically made clinically. If necessary, confirmation is easily obtained by observing budding yeast, with or without hyphae, on a wet mount or potassium hydroxide (KOH) preparation of vaginal secretions  (<a class="graphic graphic_picture graphicRef59030" href="/d/graphic/59030.html" rel="external">picture 8</a>). (See  <a class="medical medical_review" href="/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Clinical features'</a>.)</p><p>The treatment of <em>Candida</em> vulvovaginitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection"</a>.)</p><p class="headingAnchor" id="H364112986"><span class="h1">BALANITIS</span><span class="headingEndMark"> — </span><em>Candida</em> balanitis may occur as a component of diaper dermatitis in infants. It also may be acquired sexually in adolescents. Clinical features include white patches on the penis in association with severe burning and itching. The infection can spread to the thighs, gluteal folds, buttocks, and scrotum.</p><p>The diagnosis and treatment of <em>Candida</em> balanitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6483.html" rel="external">"Balanitis and balanoposthitis in children and adolescents: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ESOPHAGITIS</span><span class="headingEndMark"> — </span>Esophageal candidiasis occurs predominantly in individuals with hematologic malignancies and HIV. In patients with HIV infection, esophageal candidiasis is an acquired immunodeficiency syndrome (AIDS)-defining illness. (See  <a class="medical medical_review" href="/d/html/5963.html" rel="external">"Pediatric HIV infection: Classification, clinical manifestations, and outcome", section on 'Esophageal candidiasis'</a>.)</p><p>The hallmark of <em>Candida</em> esophagitis is pain with swallowing (odynophagia). Patients usually localize their pain to a discrete retrosternal area. Concomitant thrush may or may not be present.</p><p><em>Candida</em> esophagitis usually is diagnosed endoscopically. White mucosal plaque-like lesions suggest the diagnosis. Confirmatory biopsy demonstrates yeasts and pseudohyphae invading mucosal cells. An alternative diagnostic approach in HIV/AIDS patients with suggestive clinical features is to treat with systemic antifungal agents (eg, <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> loading dose of 6 mg/kg orally on the first day, followed by 3 mg/kg orally once per day). Odynophagia due to candidiasis typically improves within several days; if symptoms do not improve within three to four days, endoscopy and biopsy should be performed [<a href="#rid16">16</a>]. If endoscopy reveals clinical features suggestive of candidiasis, treatment with an antifungal agent other than fluconazole may be warranted pending culture results. (See  <a class="medical medical_review" href="/d/html/3726.html" rel="external">"Evaluation of the patient with HIV, odynophagia, and dysphagia", section on 'Management'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CHRONIC MUCOCUTANEOUS CANDIDIASIS</span><span class="headingEndMark"> — </span>Chronic mucocutaneous candidiasis is a rare syndrome that usually has its onset in childhood. Some patients with chronic mucocutaneous candidiasis have autosomal recessive polyglandular autoimmune syndrome type I (which may be manifested by hypoparathyroidism, hypothyroidism, and adrenal insufficiency), whereas others have no associated diseases. (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a> and  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'</a>.)</p><p>An underlying T cell defect is thought to be responsible for the inability of these patients to eradicate <em>Candida</em> from mucous membranes and cutaneous structures [<a href="#rid17">17</a>]. The clinical manifestations are severe, recurrent thrush  (<a class="graphic graphic_picture graphicRef59947" href="/d/graphic/59947.html" rel="external">picture 9</a>), vaginitis, onychomycosis  (<a class="graphic graphic_picture graphicRef71698" href="/d/graphic/71698.html" rel="external">picture 10</a>), and chronic skin lesions. Hyperkeratotic, crusted skin lesions on the face, scalp, and hands can lead to psychosocial problems  (<a class="graphic graphic_picture graphicRef64895" href="/d/graphic/64895.html" rel="external">picture 11</a>). Visceral invasion is rare. Chronic suppressive antifungal treatment is required to achieve remission. (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1200993"><span class="h1">INVASIVE CANDIDIASIS</span></p><p class="headingAnchor" id="H1198823"><span class="h2">Candidemia and acute disseminated candidiasis</span><span class="headingEndMark"> — </span>Candidemia refers to the presence of <em>Candida</em> species in the blood. Neonates, immunocompromised hosts, and children in intensive care units are most at risk for the development of candidemia. Acute disseminated candidiasis occurs when several viscera are infected as a result of hematogenous spread. (See  <a class="medical medical_review" href="/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p>The clinical manifestations of candidemia vary from minimal fever to a fulminant sepsis syndrome indistinguishable from severe bacterial infection. Signs of multiorgan system failure may be present. Clinical clues include characteristic eye lesions  (<a class="graphic graphic_picture graphicRef58685 graphicRef73318" href="/d/graphic/58685.html" rel="external">picture 12A-B</a>), skin lesions  (<a class="graphic graphic_picture graphicRef55977 graphicRef75717" href="/d/graphic/55977.html" rel="external">picture 13A-B</a>), and, less commonly, muscle abscesses. The clinical manifestations and treatment of candidemia are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/6014.html" rel="external">"Candidemia and invasive candidiasis in children: Management"</a>.)</p><p class="headingAnchor" id="H1201712"><span class="h2">Invasive focal infections</span></p><p class="headingAnchor" id="H12"><span class="h3">Urinary tract infections</span><span class="headingEndMark"> — </span>Candiduria is common in hospitalized patients, but it is difficult to distinguish colonization from infection of the bladder [<a href="#rid18">18</a>]. Risk factors for candiduria include indwelling bladder catheter, antibiotics, diabetes, and recent surgery [<a href="#rid19">19</a>].</p><p><em>Candida</em> pyelonephritis is rare. It can be secondary to hematogenous seeding and is typically characterized by multiple microabscesses in the setting of disseminated candidiasis. It can also occur as an ascending infection in patients with obstruction. Ascending infection usually is unilateral and develops more insidiously than hematogenous infection. Although <em>Candida</em> infection of the bladder and <em>Candida</em> pyelonephritis may coexist, it is important to distinguish them because the treatments differ. The symptoms of <em>Candida</em> pyelonephritis are similar to those of bacterial pyelonephritis: fever, chills, flank pain, and dysuria. (See  <a class="medical medical_review" href="/d/html/2415.html" rel="external">"Candida infections of the bladder and kidneys", section on 'Clinical characteristics'</a> and  <a class="medical medical_review" href="/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis", section on 'Clinical presentation'</a>.)</p><p>Patients with either lower or upper tract infection due to <em>Candida</em> can develop fungus balls that consist of masses of hyphae. Fungus balls can grow to a large size and lead to obstruction of the collecting system; surgical intervention or percutaneous drainage is required when obstruction occurs.</p><p>The diagnosis and treatment of <em>Candida</em> infections of the bladder and kidneys are discussed separately. (See  <a class="medical medical_review" href="/d/html/2415.html" rel="external">"Candida infections of the bladder and kidneys"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Peritonitis</span><span class="headingEndMark"> — </span><em>Candida</em> infection of the peritoneal cavity can occur as a result of postoperative wound infection, gastrointestinal perforation, or chronic peritoneal dialysis [<a href="#rid20">20,21</a>]. Peritonitis associated with primary perforation or secondary to a surgical procedure is usually polymicrobial. Prominent symptoms include fever, chills, and abdominal pain. These are the same as those of bacterial peritonitis, which is often coexistent. Complications of <em>Candida</em> peritonitis include bloodstream invasion with sepsis and abscess formation requiring surgical drainage. Diagnosis is best made by aspiration of fluid under computed tomographic (CT) or ultrasound guidance or at the time of surgery. Culture of <em>Candida</em> species from an indwelling drain is <strong>not</strong> adequate for the diagnosis of infection since it often reflects only colonization or contamination of the drain. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis", section on 'Laboratory findings and diagnosis'</a>.)</p><p>Patients who have indwelling Tenckhoff catheters for chronic peritoneal dialysis usually develop <em>Candida</em> peritonitis only after they have had episodes of bacterial peritonitis [<a href="#rid21">21</a>]. The symptoms may be subtle, consisting of mild abdominal pain and low-grade fever; the first signs frequently are poor flow and cloudiness of the dialysate. The diagnosis is easily made by culturing the dialysate fluid. In contrast to bacterial peritonitis in these patients, treatment with antifungal agents is rarely effective unless the catheter is removed. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Indications for catheter removal'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Endophthalmitis</span><span class="headingEndMark"> — </span><em>Candida</em> endophthalmitis can develop following trauma or eye surgery or through hematogenous seeding of the retina and choroid as a complication of candidemia. Patients with <em>Candida</em> endophthalmitis may or may not have evidence of disseminated candidiasis in other organ systems. Diagnosis requires an ophthalmologic examination. <em>Candida</em> endophthalmitis can be sight-threatening if it is not treated. Thus, the 2016 Infectious Diseases Society of America guidelines for the management of candidiasis recommend at least one dilated retinal examination, preferably by an ophthalmologist early in the course of therapy for all patients with candidemia [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Osteoarticular infections</span><span class="headingEndMark"> — </span><em>Candida</em> species infect bones and joints as a result of hematogenous seeding or exogenous inoculation during trauma, intra-articular injection, a surgical procedure, or injection drug use. <em>Candida</em> arthritis or osteomyelitis most often develops as a sequel to candidemia. Bone or joint involvement may become evident during an episode of fungemia or may have a more subtle presentation after the fungemia has resolved [<a href="#rid22">22-24</a>]. Swelling and decreased range of motion are the major symptoms (as in bacterial osteoarticular infections), but these may be mild [<a href="#rid25">25</a>]. Radiographic findings do not distinguish between bacterial and fungal infection. The etiologic diagnosis is established by obtaining synovial fluid or bone aspirate for culture. Even a single colony of <em>Candida</em> on culture of joint fluid or bone aspirate should be viewed as pathogenic, and the patient should be treated with antifungal agents. (See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/6064.html" rel="external">"Hematogenous osteomyelitis in children: Clinical features and complications", section on 'Clinical features'</a>.)</p><p><em>Candida</em> osteoarticular infections in neonates are discussed separately. (See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates", section on 'Other focal infections'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Meningitis/central nervous system infection</span><span class="headingEndMark"> — </span><em>Candida</em> species can cause acute meningitis during the course of widespread dissemination. <em>Candida</em> meningitis most often occurs in neonates with candidemia. (See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates", section on 'Central nervous system infection'</a>.)</p><p><em>Candida</em> species uncommonly can cause ventriculoperitoneal shunt infections [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/2453.html" rel="external">"Candida infections of the central nervous system", section on 'CNS shunts and other devices'</a>.)</p><p class="headingAnchor" id="H1198646"><span class="h3">Endocarditis</span><span class="headingEndMark"> — </span>Risk factors for <em>Candida</em> endocarditis include indwelling central venous catheters, underlying congenital heart disease, and a history of cardiac surgery [<a href="#rid27">27-29</a>]. The clinical manifestations of <em>Candida</em> endocarditis are similar to those of bacterial endocarditis. They include fever, changing or new heart murmurs, and signs and symptoms of heart failure. (See  <a class="medical medical_review" href="/d/html/5768.html" rel="external">"Infective endocarditis in children", section on 'Clinical manifestations'</a>.) Peripheral embolization is more likely with candidal than with bacterial endocarditis, and affected patients can develop other complications of candidemia (eg, visual loss secondary to endophthalmitis). (See <a class="local">'Endophthalmitis'</a> above.)</p><p>The diagnostic criteria for <em>Candida</em> endocarditis are similar to those for bacterial endocarditis. Cultures of blood show persistent candidemia, and echocardiographic studies usually reveal large valvular vegetations. In some cases, an early manifestation of endocarditis is embolization of the large vegetation to a major vessel, such as the femoral artery. Examination of the embolus by histopathology shows yeasts and by culture yields <em>Candida</em> species. (See  <a class="medical medical_review" href="/d/html/5768.html" rel="external">"Infective endocarditis in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H522957355"><span class="h2">Hepatosplenic or chronic disseminated candidiasis</span><span class="headingEndMark"> — </span>Hepatosplenic candidiasis (also called chronic disseminated candidiasis) is seen almost entirely in patients with hematologic malignancies who have just recovered from an episode of neutropenia [<a href="#rid30">30</a>]. Some patients have a documented history of candidemia; in others, it is assumed that the patient was candidemic during the period of neutropenia. (See  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)", section on 'Clinical manifestations'</a>.)</p><p>The classic presentation of hepatosplenic candidiasis consists of persistent fever, which is frequently high and spiking, in a patient who was recently neutropenic and whose neutrophil count has returned to normal. The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting, and anorexia. Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration. Discrete persistent microabscesses occur in the liver, spleen, and, sometimes, kidneys.</p><p>The diagnosis can be established by visualizing multiple characteristic lucencies in the liver and spleen on ultrasonography, magnetic resonance imaging, or CT scan  (<a class="graphic graphic_diagnosticimage graphicRef61598" href="/d/graphic/61598.html" rel="external">image 1</a>). Biopsy reveals multiple granulomas  (<a class="graphic graphic_picture graphicRef81112" href="/d/graphic/81112.html" rel="external">picture 14</a>); yeasts and hyphae can be seen using special stains. Blood cultures are negative, and even culture of liver obtained at biopsy frequently is also negative.</p><p>The treatment of hepatosplenic candidiasis is discussed separately. (See  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H20556884"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15913.html" rel="external">"Patient education: Diaper rash (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/141527.html" rel="external">"Patient education: Thrush in babies and children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1176.html" rel="external">"Patient education: Diaper rash in infants and children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H552172751"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oropharyngeal candidiasis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical manifestations – Oropharyngeal candidiasis (thrush) is common in infants  (<a class="graphic graphic_picture graphicRef69465" href="/d/graphic/69465.html" rel="external">picture 1</a>). It is characterized by white plaques on the buccal mucosa, palate, tongue, or the oropharynx. Infants with thrush may be asymptomatic or may refuse to eat and swallow because of pain. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2">Thrush also may be seen in older children treated with antibiotics, inhaled glucocorticoids, chemotherapy, or radiation therapy and in children with cellular immunodeficiency. Older children may be asymptomatic or may complain of a "cottony" feeling in the mouth, loss of taste, and sometimes pain on eating and swallowing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnosis – Oropharyngeal candidiasis is usually diagnosed clinically based upon the characteristic white plaques  (<a class="graphic graphic_picture graphicRef69465" href="/d/graphic/69465.html" rel="external">picture 1</a>). If necessary, the diagnosis can be confirmed with Gram stain or potassium hydroxide (KOH) preparation demonstrating budding yeast with or without hyphae  (<a class="graphic graphic_picture graphicRef79879" href="/d/graphic/79879.html" rel="external">picture 4</a>). (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age &lt;1 month – Management of oropharyngeal candidiasis in infants &lt;1 month is discussed separately. (See  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates", section on 'Mucocutaneous candidiasis'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 1 through 11 months – For infants one through 11 months of age with oropharyngeal candidiasis, we suggest initial treatment with topical rather than systemic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We use <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> suspension  (<a class="graphic graphic_algorithm graphicRef115621" href="/d/graphic/115621.html" rel="external">algorithm 1</a>). (See <a class="local">'Infants 1 through 11 months'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age ≥12 months – For children ≥12 months, we define mild thrush as involvement of &lt;50 percent of the oral mucosa and absence of deep, erosive lesions. We define moderate/severe thrush as involvement of ≥50 percent of the oral mucosa or deep, erosive lesions  (<a class="graphic graphic_picture graphicRef116009" href="/d/graphic/116009.html" rel="external">picture 5</a>). (See <a class="local">'Children ≥12 months'</a> above.)</p><p></p><p class="bulletIndent3">For mild oropharyngeal candidiasis in immunocompetent children ≥12 months, we suggest initial treatment with topical rather than systemic antifungal therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We use <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> suspension or lozenges four times per day or <a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">clotrimazole</a> lozenges five to six times per day for 7 to 14 days  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>). (See <a class="local">'Children ≥12 months'</a> above.)</p><p></p><p class="bulletIndent3">For mild thrush in immunocompromised children ≥12 months and moderate/severe thrush in all children, we recommend systemic rather than topical antifungal therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We generally use oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> for a total of 7 to 14 days  (<a class="graphic graphic_algorithm graphicRef115622" href="/d/graphic/115622.html" rel="external">algorithm 2</a>). A different antifungal agent and evaluation for fluconazole-resistant <em>Candida</em> or immune deficiency may be warranted if the child does not respond to empiric fluconazole. (See <a class="local">'Children ≥12 months'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diaper dermatitis</strong><em> – Candida</em> diaper dermatitis is common in young infants. Clinical features include involvement of the inguinal folds, confluent erythema with discrete papules, plaques, satellite lesions, and superficial scale  (<a class="graphic graphic_picture graphicRef59361 graphicRef72165" href="/d/graphic/59361.html" rel="external">picture 6A-B</a>). Persistent <em>Candida</em> diaper rash may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immunodeficiency. (See  <a class="medical medical_review" href="/d/html/5795.html" rel="external">"Diaper dermatitis", section on 'Secondary infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intertrigo</strong> – Clinical features of <em>Candida</em> intertrigo include erythematous, macerated plaques and erosions with peripheral scale, and satellite papulopustules  (<a class="graphic graphic_picture graphicRef62523" href="/d/graphic/62523.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/d/html/115366.html" rel="external">"Intertrigo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vulvovaginitis</strong> – Predisposing factors for vulvovaginal candidiasis in infants include diaper use, broad-spectrum antibiotics, and immunosuppression (including glucocorticoids and HIV infection). Additional risk factors in adolescents include certain contraceptive devices (vaginal sponges, diaphragms, intrauterine devices), estrogen therapy (including oral contraceptives), and pregnancy. Clinical features include itching, dysuria, vaginal irritation, vulvar erythema and swelling, vaginal erythema, and vaginal discharge. The diagnosis is typically made clinically but can be confirmed with a wet mount or KOH preparation of vaginal secretions demonstrating budding yeast, with or without hyphae  (<a class="graphic graphic_picture graphicRef59030" href="/d/graphic/59030.html" rel="external">picture 8</a>). (See <a class="local">'Vulvovaginitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophagitis</strong> – Esophageal candidiasis occurs predominantly in individuals with hematologic malignancies and HIV infection. Retrosternal pain with swallowing is the hallmark clinical feature. The diagnosis is usually made endoscopically. However, in patients with HIV infection, a trial of systemic antifungal therapy may obviate the need for endoscopy. (See <a class="local">'Esophagitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic mucocutaneous candidiasis</strong> – Clinical manifestations of chronic mucocutaneous candidiasis include severe, recurrent thrush  (<a class="graphic graphic_picture graphicRef59947" href="/d/graphic/59947.html" rel="external">picture 9</a>), vaginitis, onychomycosis  (<a class="graphic graphic_picture graphicRef71698" href="/d/graphic/71698.html" rel="external">picture 10</a>), and chronic skin lesions  (<a class="graphic graphic_picture graphicRef64895" href="/d/graphic/64895.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidemia and invasive focal infections</strong> – Candidemia refers to the presence of <em>Candida</em> species in the blood. Neonates, immunocompromised hosts, and children in intensive care units are at greatest risk. The clinical manifestations vary from minimal fever to a fulminant sepsis syndrome indistinguishable from severe bacterial infection. Clinical clues to candidemia include characteristic eye lesions  (<a class="graphic graphic_picture graphicRef58685 graphicRef73318" href="/d/graphic/58685.html" rel="external">picture 12A-B</a>), skin lesions  (<a class="graphic graphic_picture graphicRef55977 graphicRef75717" href="/d/graphic/55977.html" rel="external">picture 13A-B</a>), and, less commonly, muscle abscesses. (See  <a class="medical medical_review" href="/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6014.html" rel="external">"Candidemia and invasive candidiasis in children: Management"</a>.)</p><p></p><p class="bulletIndent1">Invasive focal infections may occur after trauma, surgical procedures, or hematogenous spread in patients with anatomic abnormalities or prosthetic devices. (See <a class="local">'Invasive focal infections'</a> above.)</p><p></p><p class="headingAnchor" id="H1533837864"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Carol Kauffman, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li class="breakAll">Fisher BT, Smith PB, Zaoutis TE. Candidiasis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier   2018, Philadelphia 2018. p.2030.</li><li><a class="nounderline abstract_t">Su CW, Gaskie S, Jamieson B, Triezenberg D. Clinical inquiries. What is the best treatment for oral thrush in healthy infants? J Fam Pract 2008; 57:484.</a></li><li class="breakAll">Health Canada warns Canadians of potential cancer risk associated with gentian violet. Available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70179a-eng.php (Accessed on June 12, 2019).</li><li><a class="nounderline abstract_t">Horsfield P, Logan FA, Newey JA. Letter: Oral irritation with gentian violet. Br Med J 1976; 2:529.</a></li><li><a class="nounderline abstract_t">Leung AK. Gentian violet in the treatment of oral candidiasis. Pediatr Infect Dis J 1988; 7:304.</a></li><li><a class="nounderline abstract_t">John RW. Necrosis of oral mucosa after local application of crystal violet. Br Med J 1968; 1:157.</a></li><li><a class="nounderline abstract_t">Hoppe JE. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group. Pediatr Infect Dis J 1997; 16:288.</a></li><li><a class="nounderline abstract_t">Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002; 21:1165.</a></li><li><a class="nounderline abstract_t">Boon JM, Lafeber HN, Mannetje AH, et al. Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis. Mycoses 1989; 32:312.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Postnatal care up to 8 weeks after birth: Clinical guideline. 2015. Available at: https://www.nice.org.uk/guidance/CG37/chapter/1-Recommendations (Accessed on October 27, 2016).</li><li><a class="nounderline abstract_t">Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2010; :CD003940.</a></li><li><a class="nounderline abstract_t">Flynn PM, Cunningham CK, Kerkering T, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127:322.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. http://www.fda.gov/Drugs/DrugSafety/ucm500597.htm (Accessed on June 01, 2016).</li><li><a class="nounderline abstract_t">Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.</a></li><li><a class="nounderline abstract_t">Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.</a></li><li class="breakAll">Kirkpatrick CH. Chronic mucocutaneous candidiasis. In: Candidiasis pathogenesis, diagnosis, and treatment, Bodey GP (Ed), Raven Press, New York 1993. p.167.</li><li><a class="nounderline abstract_t">Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections--treatment. Clin Infect Dis 2011; 52 Suppl 6:S457.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.</a></li><li><a class="nounderline abstract_t">Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437.</a></li><li><a class="nounderline abstract_t">Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.</a></li><li><a class="nounderline abstract_t">Ward RM, Sattler FR, Dalton AS Jr. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 1983; 72:234.</a></li><li><a class="nounderline abstract_t">Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688.</a></li><li><a class="nounderline abstract_t">Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care 2000; 16:249.</a></li><li><a class="nounderline abstract_t">Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am 1988; 35:543.</a></li><li><a class="nounderline abstract_t">Murphy K, Bradley J, James HE. The treatment of Candida albicans shunt infections. Childs Nerv Syst 2000; 16:4.</a></li><li><a class="nounderline abstract_t">Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.</a></li><li><a class="nounderline abstract_t">Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.</a></li><li><a class="nounderline abstract_t">Aspesberro F, Beghetti M, Oberhänsli I, Friedli B. Fungal endocarditis in critically ill children. Eur J Pediatr 1999; 158:275.</a></li><li><a class="nounderline abstract_t">Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.</a></li></ol></div><div id="topicVersionRevision">Topic 5972 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625176" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical inquiries. What is the best treatment for oral thrush in healthy infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625176" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical inquiries. What is the best treatment for oral thrush in healthy infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/953673" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Letter: Oral irritation with gentian violet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368270" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gentian violet in the treatment of oral candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20791427" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Necrosis of oral mucosa after local application of crystal violet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076817" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506950" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2779612" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2779612" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069679" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636666" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636666" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145739" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502438" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502438" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498839" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Candida urinary tract infections--treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619726" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574368" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical significance of Candida isolated from peritoneum in surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602540" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866610" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917235" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966343" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3287314" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Candida: an increasingly important pathogen in the nursery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10672422" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The treatment of Candida albicans shunt infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118386" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fungal endocarditis: evidence in the world literature, 1965-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fungal endocarditis in premature infants: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10206122" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fungal endocarditis in critically ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276268" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hepatic candidiasis in cancer patients: the evolving picture of the syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
